State of the art and development of a drug-drug interaction large scale predictor based on 3D pharmacophoric similarity

Current Drug Metabolism

Volumn 15, Issue 5, 2014, Pages 490-501

  Vilar, Santiago ^a,b   Uriarte, Eugenio ^b   Santana, Lourdes ^b   Friedman, Carol ^a   Tatonetti, Nicholas P ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

3D structure; Adverse drug event; Drug drug interaction; Pharmacophore; Shape screening

Indexed keywords

ACENOCOUMAROL; AMITRIPTYLINE; ATOMOXETINE; CELECOXIB; CLOMIPRAMINE; CLOPIDOGREL; CONJUGATED ESTROGEN; DESOGESTREL; DOPAMINE; DULOXETINE; ELETRIPTAN; ESCITALOPRAM; ETONOGESTREL; FENOFIBRATE; FENOPROFEN; HYDROCODONE; HYDROCORTISONE; LEVOFLOXACIN; MESORIDAZINE; METARAMINOL; PHENDIMETRAZINE; PHENOBARBITAL; PIOGLITAZONE; PRAZOSIN; QUETIAPINE; SILDENAFIL; SULFAMETHOXAZOLE; TOLBUTAMIDE; UNINDEXED DRUG; VENLAFAXINE;

ARTICLE; DRUG ANTAGONISM; DRUG CONFORMATION; DRUG DATABASE; DRUG INTERACTION; DRUG POTENTIATION; DRUG STRUCTURE; METHODOLOGY; PATIENT SAFETY; PHARMACOPHORE; PREDICTION; VALIDATION STUDY; CHEMICAL STRUCTURE; CONFORMATION; HUMAN;

DATABASES, PHARMACEUTICAL; DRUG INTERACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION;

EID: 84924596658     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021505141126102223     Document Type: Article

References (55)

1. Tatonetti, N.P.; Fernald, G.H.; Altman, R.B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J. Am. Med. Inf. Assoc., 2012, 19(1), 79-85
2. Pirmohamed, M. ML O: Drug Interactions of Clinical Importance; Chapman & Hall: London, 1998
3. Percha, B. and Altman, R.B. Informatics confronts drug-drug interactions. Trends Pharmacol. Sci., 2013, 34(3), 178-184
4. Staffa, J.A.; Chang, J.; Green, L. Cerivastatin and reports of fatal rhabdomyolysis. New Engl. J. Med., 2002, 346(7), 539-540
5. Vilar, S.; Harpaz, R.; Chase, H.S.; Costanzi, S.; Rabadan, R.; Friedman, C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc., 2011, 18(Suppl 1), i73-80
6. Dave, K. and Panchal, H. ENZPRED-Enzymatic Protein Class Predicting by Machine Learning. Curr. Top. Med. Chem., 2013, 13(14), 1674-1680
7. Vilar, S.; Harpaz, R.; Santana, L.; Uriarte, E.; Friedman, C., Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One, 2012, 7(7), e41471
8. Santana, L.; Gonzalez-Diaz, H.; Quezada, E.; Uriarte, E.; Yanez, M.; Vina, D.; Orallo, F. Quantitative Structure-Activity Relationship and Complex Network Approach to Monoamine Oxidase A and B Inhibitors. J. Med. Chem., 2008, 51(21), 6740-6751
9. Steffen, A.; Kogej, T.; Tyrchan, C.; Engkvist, O. Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data. J. Chem. Inf. Model., 2009, 49(2), 338-347
10. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des., 2006, 20(10-11), 647-671
11. Bolton, E.E.; Chen, J.; Kim, S.; Han, L.; He, S.; Shi, W.; Simonyan, V.; Sun, Y.; Thiessen, P.A.; Wang, J.; Yu, B.; Zhang, J.; Bryant, S.H. PubChem3D: a new resource for scientists. J. Cheminform., 2011, 3(1), 32
12. Kim, S.; Bolton, E.E.; Bryant, S.H. PubChem3D: Biologically relevant 3-D similarity. J. Cheminform., 2011, 3(1), 26
13. Kim, S.; Bolton, E.E.; Bryant, S.H. PubChem3D: conformer ensemble accuracy. J. Cheminform., 2013, 5(1), 1
14. Vilar, S.; Harpaz, R.; Uriarte, E.; Santana, L.; Rabadan, R.; Friedman, C. Drug-drug interaction through molecular structure similarity analysis. J. Am. Med. Inform. Assoc., 2012, 19(6), 1066-1074
15. Vilar, S.; Uriarte, E.; Santana, L.; Tatonetti, N.P.; Friedman, C. Detection of drug-drug interactions by modeling interaction profile fingerprints. PLoS One, 2013, 8(3), e58321
16. Schrödinger package, version 9.2, Schrödinger, LLC, New York, USA, 2011. (http://www.schrodinger.com/) (Accessed March 01, 2013)
17. DrugBank database, version 3.0. (http://www.drugbank.ca/) (Accessed Apr 01, 2011)
18. Fowler, S. and Zhang, H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: Current status on methodologies and their utility for predicting drug-drug interactions. AAPS J., 2008, 10(2), 410-424
19. Zhang, L.; Zhang, Y.; Zhao, P.; Huang, S.-M. Predicting Drug- Drug Interactions: An FDA Perspective. AAPS J., 2009, 11(2), 300-306
20. Brown, H.S.; Ito, K.; Galetin, A.; Houston, J.B. Prediction of in vivo drug-drug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol., 2005, 60(5), 508-518
21. Ito, K.; Brown, H.S.; Houston, J.B. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol., 2004, 57(4), 473-486
22. Lu, C.; Miwa, G.T.; Shimoga, R.P.; Gan, L.S.; Balani, S.K. A novel method for the prediction of drug-drug interactions in humans based on in vitro cytochrome P450 phenotypic data. Drug Metab. Dispos., 2007, 35(1), 79-85
23. Obach, R.S.; Walsky, R.L.; Venkatakrishnan, K.; Gaman, E.A.; Houston, J.B.; Tremaine, L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 2006, 316(1), 336-348
24. Marathe, P.H. and Rodrigues, A.D. In vivo animal models for investigating potential CYP3A- and Pgp- mediated drug-drug interactions. Curr. Drug Metab., 2006, 7(7), 687-704
25. Huang, S.-M.; Strong, J.M.; Zhang, L.; Reynolds, K.S.; Nallani, S.; Temple, R.; Abraham, S.; Al Habet, S.; Baweja, R.K.; Burckart, G.J.; Chung, S.; Colangelo, P.; Frucht, D.; Green, M.D.; Hepp, P.; Karnaukhova, E.; Ko, H.-S.; Lee, J.-I.; Marroum, P.J.; Norden, J.M.; Qiu, W.; Rahman, A.; Sobel, S.; Stifano, T.; Thummel, K.; Wei, X.-X.; Yasuda, S.; Zheng, J.H.; Zhao, H.; Lesko, L.J. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 2008, 48(6), 662-670
26. Imming, P.; Sinning, C.; Meyer, A. Opinion - Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov., 2006, 5(10), 821-834
27. Minto, C.F.; Schnider, T.W.; Short, T.G.; Gregg, K.M.; Gentilini, A.; Shafer, S.L. Response surface model for anesthetic drug interactions. Anesthesiology, 2000, 92(6), 1603-1616
28. Jonker, D.M.; Visser, S.A.G.; van der Graaf, P.H.; Voskuyl, R.A.; Danhof, M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther., 2005, 106 (1), 1-18
29. Hudelson, M.G.; Ketkar, N.S.; Holder, L.B.; Carlson, T.J.; Peng, C.-C.; Waldher, B.J.; Jones, J.P. High confidence predictions of drug-drug interactions: Predicting affinities for cytochrome P450 2C9 with multiple computational methods. J. Med. Chem., 2008, 51(3), 648-654
30. Korhonen, L.E.; Rahnasto, M.; Mahonen, N.J.; Wittekindt, C.; Poso, A.; Juvonen, R.O.; Raunio, H. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J. Med. Chem., 2005, 48(11), 3808-3815
31. Rahnasto, M.; Raunio, H.; Poso, A.; Wittekindt, C.; Juvonen, R.O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem., 2005, 48(2), 440-449
32. De Groot, M.J.; Alex, A.A.; Jones, B.C. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem., 2002, 45(10), 1983-1993
33. Wanchana, S.; Yamashita, F.; Hashida, M. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Pharm. Res., 2003, 20(9), 1401-1408
34. Korolev, D.; Balakin, K.V.; Nikolsky, Y.; Kirillov, E.; Ivanenkov, Y.A.; Savchuk, N.P.; Ivashchenko, A.A.; Nikolskaya, T. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem., 2003, 46(17), 3631-3643
35. Yap, C.W. and Chen, Y.Z. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model., 2005, 45(4), 982-992
36. Afzelius, L.; Zamora, I.; Ridderstrom, M.; Andersson, T.B.; Karlen, A.; Masimirembwa, C.M. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and threedimensional quantitative structure-activity relationship analysis. Mol. Pharmacol., 2001, 59(4), 909-919
37. De Rienzo, F.; Fanelli, F.; Menziani, M.C.; De Benedetti, P.G. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J. Comput. Aided Mol. Des., 2000, 14(1), 93-116
38. Williams, P.A.; Cosme, J.; Ward, A.; Angove, H.C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424(6947), 464-468
39. Williams, P.A.; Cosme, J.; Vinkovic, D.M.; Ward, A.; Angove, H.C.; Day, P.J.; Vonrhein, C.; Tickle, I.J.; Jhoti, H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 2004, 305(5684), 683-686
40. Arimoto, R. Computational models for predicting interactions with cytochrome p450 enzyme. Curr. Top. Med. Chem., 2006, 6(15), 1609-1618
41. Adverse Event Reporting System, U.S. Food and Drug Administration (FDA). (http://www.fda.gov/cder/aers/default.htm) (Accessed May 01, 2013)
42. Harpaz, R.; Chase, H.S.; Friedman, C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics, 2010, 11(Suppl 9), S7
43. Arikuma, T.; Yoshikawa, S.; Azuma, R.; Watanabe, K.; Matsumura, K.; Konagaya, A. Drug interaction prediction using ontol ogy-driven hypothetical assertion framework for pathway generation followed by numerical simulation. BMC Bioinformatics, 2008, 9 (Suppl 6), S11
44. Percha, B.; Garten, Y.; Altman, R.B. Discovery and explanation of drug-drug interactions via text mining. Pac. Symp. Biocomput., 2012, 410-421
45. Tari, L.; Anwar, S.; Liang, S.; Cai, J.; Baral, C. Discovering drugdrug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics, 2010, 26(18), i547-i553
46. Gottlieb, A.; Stein, G.Y.; Oron, Y.; Ruppin, E.; Sharan, R. INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol. Syst. Biol., 2012, 8, 592
47. LigPrep, version 2.5, Schrödinger, LLC, New York, USA, 2011. (http://www.schrodinger.com/) (Accessed March 01, 2013)
48. Kaminski, G.A.; Friesner, R.A.; Tirado-Rives, J.; Jorgensen, W.L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B, 2001, 105(28), 6474-6487
49. MacroModel, version 9.9, Schrödinger, LLC, New York, NY, 2011. (http://www.schrodinger.com/) (Accessed March 01, 2013)
50. Phase, version 3.3, Schrödinger, LLC, New York, USA, 2011. (http://www.schrodinger.com/) (Accessed March 01, 2013)
51. Pharmaceutical Sales 2010, Drugs.com database. (http://www. drugs.com/top200-units.html) (Accessed May 15, 2012).
52. Drugdex ® System (Micromedex Healthcare Series). Greenwood Village, CO: Thomson Reuters (Healthcare) Inc., 2011. (Accessed Jun 15, 2012)
53. Drug Information Online, Drugs.com database. (http://www. drugs.com/) (Accessed Jun 01, 2012)
54. Olvey, E.L.; Clauschee, S.; Malone, D.C. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther., 2010, 87(1), 48-51
55. Hellbom, E. Chlorpheniramine, selective serotonin-reuptake inhibitors (SSRIs) and over-The-counter (OTC) treatment. Med. Hypotheses, 2006, 66(4), 689-690.